USPs that matters:

New: Rare Earth-Themefolio

Advanced IPO-Section: Equities & ETF (link)

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

Short Selling Radar

IPO InfoDataHub

Powerful & free of charge: Tools 4 WebMaster ...

Tipp: Exclusive Newswire Digest

Info-Hub

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Campus

KnowHow & Education
Advanced Event Calendar Feed
Mentoring & Coaches

Press

FAQ

What's New

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Home
Terminal
Carl Zeiss Meditec AG

Carl Zeiss Meditec AG

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

S59229617

SEDOL

5922961

CIK

N/A

zeiss.com

LEI: 529900GRL4MZ8NMOOK95

New: Infographics X-Lab

FIGI: BBG000C7X325

AFX

Carl Zeiss Meditec AG

GICS: 35101010 · Sector: EQTY · Sub-Sector: -

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Carl Zeiss Meditec

Click to initiate

ENTERPRISE

You are not logged in. Don't worry! Click here and see what Perplexity AI knows about $AFX.

NAME

Carl Zeiss Meditec AG

ISIN

DE0005313704

TICKER

AFX

MIC

XETR

REUTERS

AFXG.DE

BLOOMBERG

AFX GR

F&G: 56

24.212,12 DAX · 17,65 Vola-Index · 117.552,11 BTC · 1,16725 EURUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading

Knock out & Barriers (IG)

TradingView ActivTrader MT4 MT5

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Thu, 07.08.2025

Carl Zeiss Meditec grows revenue and earnings in the first nine months of 2024/25 Significant recovery and further expansion of order entry compared to prior year JENA, 7 August 2025 Carl Zeiss Meditec generated revenue of €1,600.1m in the first nine months of fiscal year 2024/25 (prior year: €1,486.5m), including the DORC consolidation, c...

Research & Analysis

Tue, 13.05.2025

Carl Zeiss Meditec achieves revenue growth and stable operating profit in the first six months of 2024/25 Further recovery in order entry compared to prior year JENA, 13 May 2025 Carl Zeiss Meditec generated revenue of €1,050.5m in the first half of fiscal year 2024/25 (prior year: €947.2m), including the DORC consolidation, corresponding ...

Research & Analysis

Wed, 07.05.2025

Change of President and CEO at Carl Zeiss Meditec AG The President and CEO, Dr. Markus Weber, will step down from the Management Board, of his own accord and on the best of terms, on 31 May 2025. Starting 1 June 2025, the new President and CEO will be Maximilian Foerst, who is currently Head of ZEISS Greater China. Jena, Germany | 7 May 2025 | C...

Research & Analysis

Wed, 07.05.2025

Change of President and CEO at Carl Zeiss Meditec AG Jena, May 7, 2025 The supervisory board of Carl Zeiss Meditec AG (ISIN: DE0005313704) in today’s meeting has agreed on a change in the Management Board of the company. Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG since January 1, 2022, will turn over his position to Maxi...

Research & Analysis

Tue, 15.04.2025

Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25 Jena, April 15, 2025 In the second quarter of fiscal year 2024/25 ending March 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of around EUR 560 million (previous year: EUR 472.1 million), based on preliminary data, an increase of around 19%....

Research & Analysis

Thu, 27.02.2025

ZEISS VISUMAX 800 with SMILE pro software receives approval in China Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow enhancements. JENA,(Germany), SHANGHAI, (China), | 27 February 2025 | Carl Zeiss Meditec AG ZEISS Medical Technology announced to...

Research & Analysis

Wed, 12.02.2025

Carl Zeiss Meditec achieves slight revenue growth in first three months of 2024/25 Significant recovery in order entry and order backlog JENA, 12 February 2025 Carl Zeiss Meditec generated revenue of €490.5m in the first three months of fiscal year 2024/25 (prior year: €475.0m), corresponding to growth of +3.2% (adjusted for currency effec...

Research & Analysis

Wed, 11.12.2024

Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue- Adjusted EBIT forecast achieved Restrictive investment climate and low consumer confidence impact revenue and earnings performance JENA, 11 December 2024 Carl Zeiss Meditec generated revenue of €2,066.1m in fiscal year 2023/24 (prior year: €2,089.3m), corres...

Research & Analysis

Tue, 06.08.2024

Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue Restrictive investment climate and low consumer confidence impact revenue and earnings performance JENA, 6 August 2024 Carl Zeiss Meditec generated revenue of around €1,486.5m in the first nine months of fiscal year 2023/24 (prior year: €1,509.6m) corresp...

Research & Analysis

Mon, 17.06.2024

Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business Jena, June 17, 2024 In the first 8 months of fiscal year (FY) 2023/24 as of May 31, 2024, excluding the contribution from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), Carl Zeiss Meditec AG (ISIN: DE0005313...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

BARRISTA SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 28.383 Visitors - 22.648 Registered members - 13 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Made in Germany

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Visual Sitemap

Helpdesk

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Consumer information

Imprint

smart.AD